Cargando…
Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) homeostasis and plays a key role in acute coronary syndrome (ACS). The cardioprotective effect of PCSK9 inhibition extends beyond LDL cholesterol reduction, involving regulation of platelet function by not...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101279/ https://www.ncbi.nlm.nih.gov/pubmed/37058054 http://dx.doi.org/10.1097/MD.0000000000033026 |
_version_ | 1785025476023025664 |
---|---|
author | Wang, Wenting Luo, Ronghua Pei, Dean Huang, Qi Jin, Xinyao Wu, Yuanhong Xie, Mingbin Wang, Shisheng Sui, Xiangqian Shen, Bin |
author_facet | Wang, Wenting Luo, Ronghua Pei, Dean Huang, Qi Jin, Xinyao Wu, Yuanhong Xie, Mingbin Wang, Shisheng Sui, Xiangqian Shen, Bin |
author_sort | Wang, Wenting |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) homeostasis and plays a key role in acute coronary syndrome (ACS). The cardioprotective effect of PCSK9 inhibition extends beyond LDL cholesterol reduction, involving regulation of platelet function by not yet unraveled mechanisms. Oxidized-LDL (ox-LDL) is increased during ACS and induces platelet activation via binding to platelet surface. We will evaluate serum PCSK9 and its correlation with platelet reactivity and platelet-ox-LDL binding in Chinese ACS patients. METHOD AND DESIGN: In this pilot cross-sectional study, we will enroll 115 Chinese participants aged 30 to 75 years with ACS. Blood sample will be obtained after the first maintenance dose of aspirin and clopidogrel during morning time. Serum PCSK9 will be measured by an enzyme-linked immunoadsorbent assay. Platelet reactivity will be assessed by; Platelet activation (P-selectin and GPIIbIIIa expression using flow cytometry) and; Platelet aggregation using light transmission aggregometry in response to various stimuli. On-treatment platelet reactivity is measured by adenosine diphosphate-induced platelet aggregation. Binding of ox-LDL to platelet will be evaluated by flow cytometry. Spearman correlations will be used to determine association of serum PCSK9 with platelet functional parameters and platelet-ox-LDL binding. Additionally, continuous PCSK9 levels will be categorized into tertiles of equal size to investigate its association with on-treatment platelet reactivity. DISCUSSION: This study will reveal possible relationship between serum PCSK9 and platelet reactivity in the setting of ACS which may shed light on therapeutic potential in platelet inhibition by targeting PCSK9. The study will also explore the association of serum PCSK9 and platelet-ox-LDL binding, an important mechanism for platelet-LDL interplay, to provide mechanistic insight into PCSK9-mediated regulation of platelet reactivity. |
format | Online Article Text |
id | pubmed-10101279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101012792023-04-14 Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes Wang, Wenting Luo, Ronghua Pei, Dean Huang, Qi Jin, Xinyao Wu, Yuanhong Xie, Mingbin Wang, Shisheng Sui, Xiangqian Shen, Bin Medicine (Baltimore) 3400 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) homeostasis and plays a key role in acute coronary syndrome (ACS). The cardioprotective effect of PCSK9 inhibition extends beyond LDL cholesterol reduction, involving regulation of platelet function by not yet unraveled mechanisms. Oxidized-LDL (ox-LDL) is increased during ACS and induces platelet activation via binding to platelet surface. We will evaluate serum PCSK9 and its correlation with platelet reactivity and platelet-ox-LDL binding in Chinese ACS patients. METHOD AND DESIGN: In this pilot cross-sectional study, we will enroll 115 Chinese participants aged 30 to 75 years with ACS. Blood sample will be obtained after the first maintenance dose of aspirin and clopidogrel during morning time. Serum PCSK9 will be measured by an enzyme-linked immunoadsorbent assay. Platelet reactivity will be assessed by; Platelet activation (P-selectin and GPIIbIIIa expression using flow cytometry) and; Platelet aggregation using light transmission aggregometry in response to various stimuli. On-treatment platelet reactivity is measured by adenosine diphosphate-induced platelet aggregation. Binding of ox-LDL to platelet will be evaluated by flow cytometry. Spearman correlations will be used to determine association of serum PCSK9 with platelet functional parameters and platelet-ox-LDL binding. Additionally, continuous PCSK9 levels will be categorized into tertiles of equal size to investigate its association with on-treatment platelet reactivity. DISCUSSION: This study will reveal possible relationship between serum PCSK9 and platelet reactivity in the setting of ACS which may shed light on therapeutic potential in platelet inhibition by targeting PCSK9. The study will also explore the association of serum PCSK9 and platelet-ox-LDL binding, an important mechanism for platelet-LDL interplay, to provide mechanistic insight into PCSK9-mediated regulation of platelet reactivity. Lippincott Williams & Wilkins 2023-04-14 /pmc/articles/PMC10101279/ /pubmed/37058054 http://dx.doi.org/10.1097/MD.0000000000033026 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 3400 Wang, Wenting Luo, Ronghua Pei, Dean Huang, Qi Jin, Xinyao Wu, Yuanhong Xie, Mingbin Wang, Shisheng Sui, Xiangqian Shen, Bin Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes |
title | Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes |
title_full | Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes |
title_fullStr | Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes |
title_full_unstemmed | Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes |
title_short | Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes |
title_sort | association of serum pcsk9 levels with platelet function in patients with acute coronary syndromes |
topic | 3400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101279/ https://www.ncbi.nlm.nih.gov/pubmed/37058054 http://dx.doi.org/10.1097/MD.0000000000033026 |
work_keys_str_mv | AT wangwenting associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT luoronghua associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT peidean associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT huangqi associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT jinxinyao associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT wuyuanhong associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT xiemingbin associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT wangshisheng associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT suixiangqian associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes AT shenbin associationofserumpcsk9levelswithplateletfunctioninpatientswithacutecoronarysyndromes |